AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Convatec Group PLC

Board/Management Information Apr 3, 2020

4959_dirs_2020-04-03_8f66b338-2200-4b69-8a11-c86ab8d70a84.html

Board/Management Information

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7477I

ConvaTec Group PLC

03 April 2020

ConvaTec Director Declaration

Reading, United Kingdom (3 April 2020)

ConvaTec Group Plc ("ConvaTec" or "the Company") announces that Dr Ros Rivaz, a Non-Executive Director of the Company, has accepted a nomination to be appointed to the Board of Aperam S.A., as a Non-Executive Director, subject to a shareholder vote on 5 May 2020.

This announcement is made in accordance with Listing Rule 9.6.14R.

Enquiries

Analysts and Investors

Mark Reynolds, Director Investor Relations, ConvaTec            +44 (0)7551 036 625

[email protected]

Media

Buchanan: Charles Ryland / Chris Lane / Vicky Haynes           +44 (0)207 466 5000                                                                                                 

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RDNUPUCACUPUUBW

Talk to a Data Expert

Have a question? We'll get back to you promptly.